PAGE 胶长加样枪头1盒说明书公司提供的RNA/DNA 提取产品齐全，*，质量保证，欢迎广大科研用户订购！

PAGE 胶长加样枪头1盒​说明书
1  柱式DNA提取系列产品
2  柱式RNA提取系列（包括动物，血液，植物，细菌RNA提取）
3  5分钟超快DNA电泳液
4  一步式质粒DNA提取系列产品
5  “绿如蓝”DNA染料
6  固相RNase清除剂
PAGE 胶长加样枪头1盒​说明书公司的产品目前有下面10个系列，5000余种产品
1、RNA纯化系列产品
2、DNA纯化系列产品
3、电泳及回收系列产品
4、探针标记及检测系列产品
5、核酸扩增系列产品
6、克隆表达系列产品
7、基因组研究系列产品
8、蛋白质研究系列产品
9、细胞生物学研究系列产品
10、即用型溶液、质粒库、菌种库等等
的详细介绍：

IGF-I Receptor beta    胰岛素样生长因子1受体β/IGF-IRβ 试剂盒
ING4    ING4试剂盒
rat IgA    大鼠血清型IgA试剂盒
MDA7/IL-24/IL-17F    白介素-17F试剂盒
IGFL1    胰岛素生长因子样家族成员1试剂盒
IL-17C    白介素-17C试剂盒
ADM2    中介素试剂盒
IkB beta    NF-kappa-B抑制子beta试剂盒
IRF6    干扰素调节因子6试剂盒
IGFL4    胰岛素生长因子样家族成员4试剂盒
IL-31    白细胞介素31试剂盒
IFI78    干扰素诱导蛋白P78试剂盒
Inhibin Alpha    抑制素α/Inhibin α试剂盒
IL-18    白介素18试剂盒
eIF4E    真核翻译起始因子4E试剂盒
Importin4    核蛋白4试剂盒
IgHV    免疫球蛋白重链可变区试剂盒
IGFBP7    胰岛素样生长因子结合蛋白7试剂盒
IGFBP6    胰岛素样生长因子结合蛋白6试剂盒
IKB epsilon    KB抑制蛋白激酶ε
ITGB4    整合素β4试剂盒
phospho-IL-7Ra    磷酸化白细胞介素-7受体a试剂盒

transiently expressed in non-GABAergic cells of the embryonic and adult nervous system, suggesting its involvement in development and plasticity. 
GAD exists as two isoforms, GAD65 and GAD67 (molecular masses of 65 and 67 kD, respectively) that are encoded by two different genes. GAD65 is an ampiphilic, membraneanchored protein, (585 amino acid residues) and is encoded on human chromosome 10. GAD67 is a cytoplasmic protein (594 amino acid residues) and is encoded on chromosome 2. There is 64% amino acid identity between the two isoforms, with the highest diversity located at the N terminus, which in GAD65 is required for targeting the enzyme to GABA-containing secretory vesicles. The two isoforms appear to have distinct intraneuronal distribution in the brain. GAD65 has been identified as an autoantigen in insulindependent diabetes mellitus (IDDM) and stiff-man syndrome (SMS), IDDM is an autoimmune disease that results from T cell mediated destruction of pancreatic insulin-secreting beta cells. Islet-reactive T cells and antibodies primarily to GAD65 (also named beta cell autoantigen) can be detected in peripheral blood of 80% of recent-onset IDD patients and in pre-diabetic high-risk subjects before onset of clinical symptoms. This suggests